Germany Cancer Immunotherapy Market Size & Outlook

Monoclonal antibodies was the largest segment with a revenue share of 65.71% in 2023. Horizon Databook has segmented the Germany cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.

There are more than 1.4 million cancer patients in Germany, and the number continues to increase at an alarming rate. In order to reduce the cancer burden in the country, the German Cancer Consortium (DKTK) initiated the Cancer Immunotherapy (CI) Research Program.

The DKTK is a long-term initiative involving German Cancer Research Center (DKFZ), several German states, and the German Federal Ministry of Education and Research (BMBF). The organization's Joint Funding Program has supported more than 20 multicenter research studies and clinical trials since its inception in 2012.

The CI program intends to curb the growing cancer incidence using immunotherapy. Some of the key areas of focus in this program are combinatorial immunotherapy approaches, cellular therapeutics, tumor vaccines, and therapeutic antibodies. The R&D sector in oncology in Germany is likely to experience rapid growth, which is likely to propel the growth of cancer immunotherapy market over the forecast period.